For ARDS, there is a published study showing benefit of dexamethasone on both reduction in ventilation days and survival. The study was randomized controlled trial of 277 patients in Spain.

The mean number of ventilator-free days was higher in the dexamethasone group than in the control group (between-group difference 4·8 days [95% CI 2·57 to 7·03]; p<0·0001).

At 60 days, 29 (21%) patients in the dexamethasone group and 50 (36%) patients in the control group had died (between-group difference -15·3% [-25·9 to -4·9]; p=0·0047).

The proportion of adverse events did not differ significantly between the dexamethasone group and control group.

Written by

Ph.D. scientist with a passion for scientific communication and > 20 years editorial experience

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store